# Quantifying Genomic Fidelity: A Normalized Post-Edit Validation Algorithm for CRISPR-Cas9 Therapeutics in iPSCs

## Project Abstract
CRISPR-Cas9 translation in induced pluripotent stem cells (iPSCs) is constrained by an unresolved validation asymmetry: targeted sequencing panels are inexpensive and high-depth but intrinsically blind to global mutational burden, whereas whole-genome sequencing (WGS) captures genome-scale risk yet lacks a standardized index that can compare expansive search scope against local editing success. 

We developed the Precision Validation Score ($P_v$), a normalized post-edit fidelity metric defined as:

$$P_v = \frac{E_{on}}{1 + \left(\frac{M_{off}}{\log_{10}(B_s)}\right) + \frac{1}{D}}$$

Where $E_{on}$ denotes on-target efficiency, $M_{off}$ off-target mutation count, $B_s$ total base pairs sequenced, and $D$ sequencing depth. By scaling off-target penalties by $\log_{10}(B_s)$, $P_v$ mathematically buffers expansive WGS diagnostic sweeps, rewarding broader surveillance rather than penalizing WGS for discovering low-frequency background noise that narrow panels cannot observe. 

We validated this framework on an empirical GUIDE-seq/CIRCLE-seq off-target atlas, filtering and auditing 245,848 rows into 6,309 fully characterized genomic test points spanning K562, U2OS, and HEK293T cell models. An 80/20 train/test protocol blinded the baseline model to 1,262 samples and achieved $R^2 = 0.8495$ with $\text{MSE} = 0.00093$ on the held-out set, while 5-fold cross-validation confirmed stability at $R^2 = 0.8667 \pm 0.0879$. Feature coefficient analysis showed $E_{on}$ as the dominant positive driver and $M_{off}$ as the strongest negative penalty, aligning the learned model with the biological intent of $P_v$. 

Critically, a 70.9% error outlier at coordinate `chr1_99347645` revealed a hyper-efficient “perfect mistake” off-target site, defining the failure boundary of flat linear models and motivating nonlinear escalation. This milestone establishes Stage 2A migration to XGBoost for interaction-aware outlier handling and Stage 2B/2C transition to sequence-aware deep learning with Nucleotide Transformers, enabling raw ATCG guide/context ingestion and in silico safety-score prediction before guide RNAs are physically synthesized.
